Menu
This security has been delisted
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

Roche Holding AG ADR

WKN: 891106 / Symbol: RHHBY / Name: Roche / Stock / Pharmaceuticals / Large Cap /

€43.90
-1.770%

Roche Bobois S.a.

WKN: A2JQRU / Name: Roche Bobois S.a. / Stock / ? /

€25.30
-0.390%

Roche Holding AG

WKN: A4124Y / Name: Roche Holding / Stock / ? /

€15.90
0.000%

Roche Holding AG

WKN: A40CGQ / Name: Roche Holding / Stock / ? /

€7.60
-3.180%

Roche Finance Europe B.v.

WKN: A3LEL7 / Name: Roche Finance Europe B.v. / Stock / ? /

€102.31
0.070%

Roche Finance Europe B.v.

WKN: A3LEL8 / Name: Roche Finance Europe B.v. / Stock / ? /

€101.78
0.070%

Roche Finance Europe B.v.

WKN: A3LRTS / Name: Roche Finance Europe B.v. / Stock / ? /

€101.67
0.000%

Roche Finance Europe B.v.

WKN: A3LRTT / Name: Roche Finance Europe B.v. / Stock / ? /

€101.66
0.160%

Roche Finance Europe B.v.

WKN: A3LX6K / Name: Roche Finance Europe B.v. / Stock / ? /

€102.62
0.030%

Roche Finance Europe B.v.

WKN: A3LX6L / Name: Roche Finance Europe B.v. / Stock / ? /

€95.64
0.160%

Roche Holdings Inc.

WKN: A3LVX8 / Name: Roche Holdings Inc. / Stock / ? /

€97.84
0.510%

FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug
FDA Accepts Roche's NDA Seeking Approval for Breast Cancer Drug

Roche RHHBY announced that the FDA has accepted its new drug application (NDA) for giredestrant, an investigational oral therapy, in combination with everolimus, for the treatment of adult patients

Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study
Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study

Roche RHHBY recently announced that the late-stage study, FENhance 1, evaluating fenebrutinib for relapsing multiple sclerosis (RMS), met its primary endpoint.

Fenebrutinib is an experimental oral

Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal

Roche RHHBY has announced that the mid-stage study ZUPREME-1, evaluating the investigational candidate petrelintide for the treatment of obesity, met its primary endpoint.

The drug is being

Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study
Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study

Roche RHHBY announced results from a late-stage study evaluating its investigational candidate, giredestrant, in combination with palbociclib for patients with estrogen receptor (ER)-positive, human

Rochefocauld
Account activated

Top Stock Reports for Costco, Roche & Lam Research
Top Stock Reports for Costco, Roche & Lam Research

Tuesday, February 24, 2026The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Costco

The Zacks Analyst Blog Highlights Costco Wholesale, Roche, Lam Research, Spruce Power and IDT
The Zacks Analyst Blog Highlights Costco Wholesale, Roche, Lam Research, Spruce Power and IDT

For Immediate Release

Chicago, IL – February 25, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and

Roche Generalversammlung 2026
Roche Generalversammlung 2026
  • Alle Anträge des Verwaltungsrates genehmigt
  • Severin Schwan erneut als Präsident des Verwaltungsrates gewählt; alle weiteren zur Wahl stehenden Verwaltungsrätinnen und Verwaltungsräte bestätigt
  • 39.